Literature DB >> 1504712

Enteral absorption of octreotide.

G Fricker1, J Drewe, J Vonderscher, T Kissel, C Beglinger.   

Abstract

1. The somatostatin octapeptide-analogue, octreotide, is absorbed as intact peptide from the gastrointestinal (GI) tract. 2. In situ absorption experiments in rats confirmed our recent intubation studies in human volunteers demonstrating that the peptide has preferential absorption sites in the small intestine. Absorption of octreotide was higher in the jejunum than in the duodenum or the ileum. 3. Experiments with bile-duct cannulated rats demonstrated that the absorption of octreotide decreased in the presence of bile, reflecting a negative influence of biliary components on the absorption of the peptide. 4. Uptake experiments using rat jejunal brush border membranes were performed to analyse the absorption mechanisms. The transport of octreotide into jejunal brush border membranes was significantly higher than the uptake into membrane vesicles isolated from rat ileum. When initial uptake (0-15s) rates into the membrane vesicles were calculated as a function of the peptide concentration, a saturable component could be observed, indicative of transport mechanisms different from simple diffusion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1504712      PMCID: PMC1908725          DOI: 10.1111/j.1476-5381.1992.tb09057.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Characteristics of tripeptide transport in human jejunal brush-border membrane vesicles.

Authors:  D Wilson; J A Barry; K Ramaswamy
Journal:  Biochim Biophys Acta       Date:  1989-11-17

Review 2.  Clinical applications of somatostatin.

Authors:  E del Pozo
Journal:  Horm Res       Date:  1988

3.  Characterization of amino-acid transport systems in guinea-pig intestinal brush-border membrane.

Authors:  O Satoh; Y Kudo; H Shikata; K Yamada; T Kawasaki
Journal:  Biochim Biophys Acta       Date:  1989-10-16

4.  Oral absorption of the somatostatin analogue SMS 201-995: theoretical and practical implications.

Authors:  H S Fuessl; J Domin; S R Bloom
Journal:  Clin Sci (Lond)       Date:  1987-02       Impact factor: 6.124

5.  Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin.

Authors:  J Pless; W Bauer; U Briner; W Doepfner; P Marbach; R Maurer; T J Petcher; J C Reubi; J Vonderscher
Journal:  Scand J Gastroenterol Suppl       Date:  1986

6.  Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

Authors:  S W Lamberts; P Uitterlinden; L Verschoor; K J van Dongen; E del Pozo
Journal:  N Engl J Med       Date:  1985-12-19       Impact factor: 91.245

7.  Intestinal absorption of the octapeptide SMS 201-995 visualized by fluorescence derivatization.

Authors:  G Fricker; C Bruns; J Munzer; U Briner; R Albert; T Kissel; J Vonderscher
Journal:  Gastroenterology       Date:  1991-06       Impact factor: 22.682

8.  Characteristics of glycylsarcosine transport in rabbit intestinal brush-border membrane vesicles.

Authors:  V Ganapathy; G Burckhardt; F H Leibach
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

Review 9.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

10.  Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995.

Authors:  G Williams; J A Ball; J M Burrin; G F Joplin; S R Bloom
Journal:  Lancet       Date:  1986-10-04       Impact factor: 79.321

View more
  13 in total

1.  Intestinal absorption of octreotide using trimethyl chitosan chloride: studies in pigs.

Authors:  M Thanou; J C Verhoef; J H Verheijden; H E Junginger
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  Colonic absorption and bioavailability of the pentapeptide metkephamid in the rat.

Authors:  P Langguth; G Breves; A Stöckli; H P Merkle; S Wolffram
Journal:  Pharm Res       Date:  1994-11       Impact factor: 4.200

Review 3.  Novel CD9-targeted therapies in gastric cancer.

Authors:  Yoko Murayama; Kenji Oritani; Shusaku Tsutsui
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

4.  P-glycoprotein- and mrp2-mediated octreotide transport in renal proximal tubule.

Authors:  H Gutmann; D S Miller; A Droulle; J Drewe; A Fahr; G Fricker
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

Review 5.  New therapeutic agents for acromegaly.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2015-11-27       Impact factor: 43.330

6.  Permeation enhancement of octreotide by specific bile salts in rats and human subjects: in vitro, in vivo correlations.

Authors:  G Fricker; A Fahr; C Beglinger; T Kissel; G Reiter; J Drewe
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

7.  Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether.

Authors:  J Drewe; G Fricker; J Vonderscher; C Beglinger
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

8.  Effect of current magnitude and drug concentration on iontophoretic delivery of octreotide acetate (Sandostatin) in the rabbit.

Authors:  D T Lau; J W Sharkey; L Petryk; F A Mancuso; Z Yu; F L Tse
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

Review 9.  Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.

Authors:  P Chanson; J Timsit; A G Harris
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

10.  Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide.

Authors:  Peng Li; Leigh Ford; Shadabul Haque; Mitchell P McInerney; Hywel D Williams; Peter J Scammells; Philip E Thompson; Vincent Jannin; Christopher J H Porter; Hassan Benameur; Colin W Pouton
Journal:  Pharm Res       Date:  2021-06-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.